Alabama is currently home to 1297 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795
Recruiting
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
Gender:
All
Ages:
25 years and below
Trial Updated:
04/30/2024
Locations: Children's of Alabama, Birmingham, Alabama
Conditions: Low-grade Glioma
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
NCT05561114
Recruiting
To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.
Gender:
All
Ages:
22 years and above
Trial Updated:
04/30/2024
Locations: Birmingham Gastroenterology Associates, Birmingham, Alabama
Conditions: Esophageal Stricture
Register for Updates
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
NCT05533775
Recruiting
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Gender:
All
Ages:
Between 6 months and 30 years
Trial Updated:
04/30/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Mature B-Cell Non-Hodgkin Lymphoma
Register for Updates
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304
Recruiting
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Heart Center Research / Huntsville Hospital, Huntsville, Alabama
Conditions: Ischemic Stroke, Systemic Embolism
Register for Updates
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
NCT05271409
Recruiting
The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period
Gender:
All
Ages:
12 years and above
Trial Updated:
04/30/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, symptomatic AS.
Gender:
All
Ages:
65 years and above
Trial Updated:
04/30/2024
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245
Recruiting
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Gender:
All
Ages:
Between 12 years and 45 years
Trial Updated:
04/30/2024
Locations: Harmonex Neuroscience Research, Dothan, Alabama
Conditions: Autism Spectrum Disorder
Register for Updates
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
NCT05011058
Recruiting
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama
Conditions: Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, Nos, EBV Associated Lymphoma, EBV Related PTCL, Nos
Register for Updates
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04987307
Recruiting
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2024
Locations: Digestive Health Specialists of the Southeast, Dothan, Alabama
Conditions: Ulcerative Colitis
Register for Updates
Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence
NCT04930159
Recruiting
The SISTER study is a randomized trial, looking at various modalities of social support for Black patients undergoing treatment for endometrial cancer. There are three study arms: group support, 1:1 peer support, and enhanced usual care. The primary outcome is treatment completion, and the secondary outcome is social isolation.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Endometrial Cancer
Register for Updates
TTVR Early Feasibility Study
NCT04433065
Recruiting
The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama
Conditions: Tricuspid Regurgitation
Register for Updates
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT04408755
Recruiting
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/30/2024
Locations: Clinical Research Site #840-053, Birmingham, Alabama
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates